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ABSTRACT
Matrine (MT), the effective component of Sophora ﬂa-
vescens Ait, has been shown to have anti-inﬂammation,
immune-suppressive, anti-tumor, and anti-hepatic ﬁbrosis
activities. However, the pharmacological effects of MT
still need to be strengthened due to its relatively low
efﬁcacy and short half-life. In the present study, we
report a more effective thio derivative of MT, MD-1, and
its inhibitory effects on the activation of hepatic stellate
cells (HSCs) in both cell culture and animal models.
Cytological experiments showed that MD-1 can inhibit
the proliferation of HSC-T6 cells with a half-maximal
inhibitory concentration (IC50) of 62 μmol/L. In addition,
MD-1 more strongly inhibits the migration of HSC-T6
cells compared to MT and can more effectively induce
G0/G1 arrest and apoptosis. Investigating the biological
mechanisms underlying anti-hepatic ﬁbrosis in the
presence of MD-1, we found that MD-1 can bind the
epidermal growth factor receptor (EGFR) on the surface
of HSC-T6 cells, which can further inhibit the phospho-
rylation of EGFR and its downstream protein kinase B
(Akt), resulting in decreased expression of cyclin D1 and
eventual inhibition of the activation of HSC-T6 cells.
Furthermore, in rats with dimethylnitrosamine (DMN)-
induced hepatic ﬁbrosis, MD-1 slowed the development
and progression of hepatic ﬁbrosis, protecting hepatic
parenchymal cells and improving hepatic functions.
Therefore, MD-1 is a potential drug for anti-hepatic
ﬁbrosis.
KEYWORDS matrine derivative, hepatic stellate cell,
hepatic ﬁbrosis, epidermal growth factor receptor, signal
transduction pathway
INTRODUCTION
Hepatic ﬁbrosis is a pathological process comprising atypical
hyperplasia (dysplasia) of intrahepatic connective tissue and
excessive accumulation of extracellular matrix (ECM) that
can ultimately develop into hepatic cirrhosis. The main
pathogenic factors that induce hepatic ﬁbrosis include
chronic hepatitis virus (i.e., HBV and HCV) and parasite
infection (e.g., schistosomes), alcoholic liver disease, fatty
liver disease, cholestasis, drug-induced liver injury, and
autoimmune hepatitis. The persistent presence of these
factors causes the production and activation of hepatic
ﬁbrosis-initiating cells, especially the activation of hepatic
stellate cells (HSCs). Other cells that can be activated are
ﬁbroblasts, liver sinusoidal endothelial cells, and Kupffer
cells surrounding the portal vein; mesenchymal stem cells
derived from bone marrow; blood ﬁbrocytes; and hepato-
cytes or biliary epithelial cells that have undergone epithelial-
mesenchymal transition (EMT) (Fausther et al., 2013; Iwai-
sako et al., 2014b; Pinzani, 2015; Koo et al., 2016). These
cells can proliferate and transdifferentiate into myoﬁbroblasts
(MFs) and then synthesize and secret a large amount of
ECM, causing hepatic ﬁbrosis and cirrhosis (Fagone et al.,
2015).
Studies of the mechanisms underlying the development of
hepatic ﬁbrosis indicate thatmany factors associatedwith liver
injuries can induce HSC activation (Seki and Brenner, 2015).
Hepatic parenchymal cell injury can be caused by a variety of
pathological factors and induce the synthesis and release of a
variety of cytokines, including transforming growth factor β
(TGF-β), epidermal growth factor (EGF), platelet-derived
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growth factor (PDGF), endothelin (ET), ﬁbroblast growth factor
(FGF), connective tissue growth factor (CTGF), and leptin,
which can further activate the TGF-β/Smad, epidermal growth
factor receptor (EGFR), and Ras/ERK signaling pathways to
promote HSC proliferation and activity (Cuevas et al., 2011;
Handy et al., 2011; Shimada et al., 2011; Liu et al., 2013). After
activation, HSCs can transdifferentiate into MFs, which
express α-smooth muscle actin (α-SMA), secrete ECM com-
ponents (including type I and type II collagens and proteo-
glycan) that cause ECM accumulation, and promote the
development of hepatic ﬁbrosis. Therefore, inhibition of hep-
atic ﬁbrosis throughHSC inactivation is amajor direction in the
prevention and treatment of hepatic cirrhosis.
Two major treatments are used against hepatic ﬁbrosis:
those that eliminate pathogenic factors that cause hepatic
ﬁbrosis (e.g., antiviral therapy and glucocorticoid treatment of
autoimmune or alcoholic liver diseases) and those that target
ECMaccumulation by decreasing its synthesis and facilitating
its degradation. Clinical treatment measures for anti-hepatic
ﬁbrosis are currently limited. Therefore, it is crucial to explore
new types of anti-hepatic ﬁbrosis drugs. Matrine (MT), the
effective component of Sophora ﬂavescens Ait, has been
shown to have anti-inﬂammation, immune-suppressive, anti-
tumor, and anti-hepatic ﬁbrosis activities. MT also has pro-
tective effectsagainst acute liver injury inmiceand rats (Zhang
et al., 2011; Liu et al., 2014). However, the clinical pharma-
cological effects of this drug still need to be strengthened due
to its relatively low efﬁcacy and short half-life. In the present
study, we structurally modiﬁed MT and obtained a novel thio
derivative called MD-1 (C30N4H40SO5F) through thiosulfate
and side chain Michael addition to prepare maleate for anti-
hepatic ﬁbrosis experiments. We examined the effects of MD-
1 on HSC activation and inhibition of hepatic ﬁbrosis in rats. In
addition, the possible mechanism of action of this novel MT
derivative was investigated to determine if it is a potential
clinical treatment option for hepatic ﬁbrosis.
RESULTS
Inhibition of HSC-T6 cell proliferation by novel thio
derivatives of MT
A series of novel thio derivatives of MT, including MD-1, MD-
2, and MD-3, were obtained from structural modiﬁcations to
MT (Fig. 1A, also see Supplementary Information for details).
First, we determined the effects of MT and its derivatives on
the proliferation of HSC-T6 cells at a concentration of
100 µmol/L. MT treatment decreased the survival rate to
62.9% ± 10.0% (n = 3) compared to control (114.2% ± 8.5%,
n = 3; P < 0.001, Fig. 1B). Among the three derivatives of MT,
MD-1 had the strongest inhibitory effect on HSC-T6 cells,
decreasing the cell survival rate to 24.2% ± 5.0%, which is
signiﬁcantly lower than that of MT (n = 3; P = 0.004). For MD-
2 the cell survival rate was 27.4% ± 1.6% (n = 3; P < 0.01
compared to MT). The inhibitory effect of MD-3 on HSC-T6
cells was equivalent to that of MT (47.2% ± 8.1%, n = 3;
P = 0.10). We also examined the effects of different con-
centrations of MD-1 on the proliferation of HSC-T6 cells. The
survival rates of HSC-T6 cells decreased as the MD-1 con-
centration increased. The IC50 values of MD-1 and MT on
HSC-T6 cells were 62 µmol/L and 128 µmol/L, respectively
(Fig. 1C).
Inhibitory effects of MD-1 on HSC-T6 cell motility
The inhibitory effects of MD-1 and MT on the migration of
HSC-T6 cells were observed using the Transwell assay. To
exclude the inﬂuence of inhibited cell proliferation, the
experimental concentrations of MD-1 and MT were set at
their corresponding IC50 values to compare their effects on
cell migration at the same cell survival rate (50%). After 24 h
of treatment, the difference in HSC-T6 cell migration
between 62 µmol/L MD-1 and 128 µmol/L MT was not sig-
niﬁcant, but both signiﬁcantly reduced motility compared to
control (Fig. 2B; P < 0.05). However, after 48 h, the inhibitory
effect of MD-1 on cell migration was signiﬁcantly stronger
than that of MT (P < 0.05, n = 3, Fig. 2A and 2B). Comparing
the difference between 24 h and 48 h groups, the results
showed that there was a signiﬁcant different increase in MT-
treated cells at 48 h compared with that at 24 h (P < 0.01),
but not in MD-1-treated cells, suggesting a stronger effect of
MD-1 on inhibiting HSC-T6 cell migration.
Effects of MD-1 on cell cycle and apoptosis in HSC-
T6 cells
The effects of MD-1 on cell cycle and apoptosis in HSC-T6
cellsweredetectedbyﬂowcytometry.Compared to the control
group, MD-1- and MT-treated HSC-T6 cells had an increased
percentage of cells in G0/G1 phase and a decreased per-
centage of cells in theSphase (Fig. 3A). The change in the cell
cycle induced by MD-1 was even more signiﬁcant than the
change induced by MT (G0/G1: 47.2% ± 3.2% in MD-1 group,
38.6% ± 2.5% in MT group, and 25.2% ± 3.0% in control; S:
33.6% ± 4.5% in MD-1 group, 36.6% ± 2.6% in MT group, and
58.9% ± 2.2% in control; G2/M: 18.5% ± 6.0% in MD-1 group,
24.9% ± 4.5% in MT group, and 17.4% ± 1.4% in control; n = 3
in each group). These results suggest that MD-1 could induce
G0/G1 arrest inHSC-T6 cells and decrease the number of cells
entering mitosis (Fig. 3A, right). The apoptosis rate in control
HSC-T6 cells was 2.5% ± 1.3% (n = 3). After MD-1 or MT
treatment for 48 h, the apoptosis rate increased to
25.6% ± 4.8% (n = 3; P = 0.001) or 7.6% ± 2.5% (n = 3;
P < 0.05), respectively. The effect of MD-1 on the induction of
apoptosis in HSC-T6 cells was signiﬁcantly stronger than that
of MT (P = 0.005; Fig. 3B, right).
Effects of MD-1 on the EGFR signaling pathway
After biotin-labeled MD-1 was prepared, the localization of
MD-1 in HSC-T6 cells and its relationship with EGFR were
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examined by immunoﬂuorescence labeling and co-im-
munoprecipitation assay. The localization of MD-1 was
consistent with EGFR on the surface of the cell membrane
(Fig. 4A). After knocking down the expression of EGFR in
HSC-T6 cells using an EGFR-shRNA expression plasmid,
immunoﬂuorescence labeling showed that MD-1 binding to
cell membranes decreased accordingly (Fig. 4B). Co-im-
munoprecipitation blots also showed a positive band of MD-
1-Biotin was precipitated by EGFR in the MD-1-treated
cells, but not in the parental cells (Fig. 4C). These results
suggest that the target molecule of MD-1 in HSC-T6 cells
was EGFR and that the drug exerted its function by binding
to EGFR.
We also detected the expression of EGFR downstream
signaling proteins. After HSC-T6 cells were treated with MD-
1, the phosphorylation levels of cell proliferation- and motil-
ity-associated EGFR and Akt signiﬁcantly decreased (p-
EGFR: P < 0.001; t-EGFR: P < 0.05; p-AKT: P < 0.01; n = 3
in each group, Fig. 4D), and the expression levels of cell



















































































Figure 1. Novel thio derivatives of MT inhibit the proliferation of HSC-T6 cells. (A) The chemical structure of MD-1, MD-2, and
MD-3. (B) The inhibitory effects of MD-1, MD-2, and MD-3 on the proliferation of HSC-T6 cells (MD-1 group: 24.2% ± 5.0%; MD-2
group: 27.4% ± 1.6%; MD-3 group: 47.2% ± 8.1%; MT group: 62.9% ± 10.0%; control group: 114.2% ± 8.5%; n = 3 in each group).
(C) A concentration-dependent plot of the effect of MD-1 and MT on the proliferation of HSC-T6 cells. IC50 of MD-1 and MT was
62 µmol/L and 128 µmol/L, respectively.
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protein p-Smad also decreased (P < 0.01 and P < 0.05,
respectively, Fig. 4D). These results suggest that the EGFR
and Akt signaling pathways are key factors in regulating the
molecular mechanisms by which MD-1 inhibited HSC-T6 cell
proliferation, migration, and cell cycle arrest and apoptosis,
and that cyclin D1 and p-Smad were also involved.
Effects of MD-1 on ECM synthesis and secretion
in HSC-T6 cells
After activation, HSCs transdifferentiated into MFs, which
expressed α-SMA and secreted ECM. qRT-PCR demon-
strated that MD-1-treated HSC-T6 cells expressed signiﬁ-
cantly decreased levels of α-SMA mRNA (P < 0.01, n = 3,























Figure 2. Inhibitory effects of MD-1 on the motility of HSC-T6 cells. (A) Top: Representative picture to show the migration ability
of HSC-T6 cells at the same cell viability (50%) after 24 h of drug action (MD-1, MT, and control). Bottom: After 48 h of drug action.
(B) Statistics for the migration ability of HSC-T6 cells. *P < 0.05; **P < 0.01.
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Figure 3. Inhibition of cell cycle and induction of apoptosis by MD-1 in HSC-T6 cells. (A) Left: The cell cycle distribution of HSC-
T6 cells in the presence of MD-1 or MT at 62 μmol/L was examined by ﬂow cytometry. Right: Statistics for cell cycle distribution.
*P < 0.05; **P < 0.01; ***P < 0.001. (B) Left: The cell apoptosis rate was detected with ﬂow cytometer in MD-1, MTand control group.
*P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4. Inhibitory effects of MD-1 on the EGFR signaling pathway in HSC-T6 cells. (A) Immunostaining of EGFR-positive
HSC-T6 cells showed MD-1 localization. Nuclei are stained with DAPI. Scale bar: 10 µm. (B) Similar to (A), but in EGFR-knockdown
HSC-T6 cells. Scale bar: 10 µm. (C) Co-immunoprecipitation blots showed MD-1-Biotin was precipitated by EGFR in the MD-1-
treated HSC-T6 cells, but not in the parental cells. (D) Representative Western blots to show the expression of EGFR, AKT, cyclin D1,
and p-Smad. GAPDH was used as the loading control. Densitometry was performed to determine the relative expression levels
normalized to GAPDH. *P < 0.05; **P < 0.01; ***P < 0.001.















































































Figure 5. Inhibitory effects of MD-1 on ECM synthesis and secretion in HSC-T6 cells. (A) Relative expression levels of ECM
components, including α-SMA, collagen I and III, and TIMP-1, as detected by real-time quantitative PCR (qRT-PCR). *P < 0.05;
**P < 0.01. (B) Expression of ECM components in the collected cell supernatant as determined by ELISA. *P < 0.05; ***P < 0.001.
RESEARCH ARTICLE Yi Feng et al.

























































































































































































































































































































MD-1 attenuates hepatic ﬁbrosis by inhibiting EGFR activation RESEARCH ARTICLE









Fig. 5A). The expression of intracellular type I and type III
collagens was also downregulated (P < 0.01 and P < 0.05,
respectively, Fig. 5A), and the expression of tissue inhibitor
of metalloproteinase 1 (TIMP-1) was slightly decreased
(P = 0.20, n = 3, Fig. 5A). ELISA showed that the levels of α-
SMA, type I and III collagen, TIMP-1 in the MD-1-treated
cells were signiﬁcantly decreased (Fig. 5B). These results
indicated that HSC activation could be signiﬁcantly sup-
pressed by MD-1, resulting in decreased ECM synthesis and
secretion.
Effects of MD-1 on DMN-induced hepatic ﬁbrosis
in rats
A hepatic ﬁbrosis model was established in rats by repeated
intraperitoneal injection of DMN to induce hepatic ﬁbrosis.
During the initiation and progression of hepatic ﬁbrosis, the
rats were continuously treated with MD-1 or MT for 4 weeks.
Two months after completing the treatment, blood and liver
tissues were collected to examine liver function and hepatic
ﬁbrosis indicators. Van Gieson collagen staining of the liver
tissue sections showed that DMN successfully induced
hepatic ﬁbrosis, proliferated collagen ﬁbers segmented and
surrounded pseudolobules, and hepatocytes had spotty
necrosis and lymphocyte inﬁltration (Fig. 6A, positive con-
trol). Livers from MD-1-treated rats had signiﬁcantly lower
collagen ﬁber proliferation than controls, as well as narrow
septae and incomplete segmentation of pseudolobules.
However, the hepatocyte necrosis was not signiﬁcant
(Fig. 6A, MD-1 group). Based on pathological changes, the
curative effect of MT was signiﬁcantly less than that of MD-1
(Fig. 6A). Immunohistochemistry showed that the expression
of p-EGFR, p-AKT, α-SMA, and cyclin D1 was signiﬁcantly
decreased in livers from the MD-1 group compared to the
positive control group, but the expression was still higher
than that of the normal control group (negative control group,
Fig. 6B and 6C). Compared to the positive control group,
p-EGFR, p-AKT, and α-SMA were downregulated in the MT
group, whereas the reductions in cyclin D1 and p-Smad were
not signiﬁcant (Fig. 6B). ELISA showed that serum ALT, AST,
and type I collagen levels were increased in the positive
control group but signiﬁcantly decreased in the MD-1 group
while still being higher than the levels in the negative control
group (Fig. 6C). In the MT group, ALT and AST were sig-
niﬁcantly decreased, but the reduction in type I collagen was
not signiﬁcant (Fig. 6C). Our results suggest a better inhibi-
tion of hepatic ﬁbrosis in the MD-1 group than the MT group,
both of which were more effective than the positive control.
DISCUSSION
Hepatic cirrhosis resulting from chronic liver disease is dif-
ﬁcult to reverse and effective clinical treatments are lacking
(Tsochatzis et al., 2014; Crossan et al., 2015). Because
early-stage hepatic ﬁbrosis can be reversed, active screen-
ing of new treatment methods for early interventions for
hepatic ﬁbrosis can effectively reduce the incidence of
hepatic cirrhosis, or even hepatic carcinoma, improving the
quality of life for many people. Among cells involved in
hepatic ﬁbrosis, HSCs (also known as Ito cells or fat-storing
cells) in the perisinusoidal space play a critical role in the
initiation and development of hepatic ﬁbrosis (Page et al.,
2015; Koo et al., 2016). HSCs are activated by a variety of
cytokines to proliferate and transdifferentiate into MFs and
then secrete a large amount of ECM, such as collagen
ﬁbers. The interaction among cytokines, cells, and ECM
promotes the initiation and progression of hepatic ﬁbrosis,
ﬁnally resulting in hepatic cirrhosis and cancer (Iwaisako
et al., 2014a; Iwaisako et al., 2014b; Wallace and Friedman,
2014; Tang et al., 2015). Because the causes of the majority
of liver diseases, such as chronic hepatitis B and autoim-
mune hepatitis, are difﬁcult to remove, targeting the patho-
genic mechanism underlying hepatic ﬁbrosis may be an
effective measure to intervene in the disease development
process and treat hepatic ﬁbrosis. If the occurrence of hep-
atic ﬁbrosis can be delayed or prevented, the pathological
process of hepatic injury can be attenuated or treated.
Lamivudine and entecavir are antiviral drugs used for the
clinical treatment of hepatitis B that can effectively inhibit
HBV replication, with stronger binding and inhibitory effects
on DNA polymerase. Therefore, these drugs can inhibit the
development of hepatitis and hepatic ﬁbrosis (Papachrysos
et al., 2015). Inhibition of the phosphoinositide 3-kinase
(PI3K)-related signal transduction pathway using PI3K-
speciﬁc inhibitor LY294002 can signiﬁcantly inhibit HSC
proliferation (Wang et al., 2013). Gene therapy is also an
effective measure for anti-hepatic ﬁbrosis. Treatment of a rat
thioacetamide-induced hepatic ﬁbrosis model with a human
MMP-1 adenovirus plasmid was shown to signiﬁcantly
attenuate the degree of hepatic tissue ﬁbrosis, decrease the
hydroxyproline level and the number of active HSCs, pro-
mote hepatocyte proliferation, and improve liver tissue
structure (Iimuro et al., 2003). As a novel potential method,
Figure 6. Inhibitory effects of MD-1 on DMN-induced hep-
atic ﬁbrosis in rats. (A) The sectioned rat liver tissues were
stained with Van Gieson staining reagent to show the prolifer-
ated collagen ﬁbers (stained with red) segmented and sur-
rounded pseudolobules in the positive control group, and MD-1
treatment signiﬁcantly reduced the collagen ﬁbers. Original
magniﬁcation: 200×. (B) Top: Expression of p-EGFR, p-AKT, α-
SMA, cyclin D1, and p-Smad in sectioned rat liver was
examined by immunohistochemistry. The percentages of pos-
itive cells (stained with brown) were counted within ﬁve ﬁelds of
view for each section using a 20× objective lens. Original
magniﬁcation: 100×. Bottom: Statistics for p-EGFR, p-AKT, α-
SMA, cyclin D1, and p-Smad. *P < 0.05; **P < 0.01;
***P < 0.001. (C) Top: Detection of serum ALT and AST levels
on fully automated biochemical analyzer. Bottom: Detection of
collagen I by ELISA. *P < 0.05; **P < 0.01; *** P < 0.001.
b
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bone marrow mesenchymal stem cell (BMSC) transplanta-
tion has become a focus of attention (Jang et al., 2015).
Studies in a murine hepatic ﬁbrosis model showed that
BMSCs injected into the tail vein can reach the liver and
reduce the degree of hepatic ﬁbrosis (Sakaida et al., 2004).
However, the speciﬁc mechanism underlying the differenti-
ation of BMSCs into hepatocytes and the reduction in hep-
atic ﬁbrosis is still not clear, and an inﬂuence of the local
microenvironment could not be fully excluded. Because
intrahepatic inﬂammation is persistent in the majority of
patients, BMSCs circulate to the liver, where they are acti-
vated by a variety of cytokines and induced to differentiate
into MFs, which become a factor in the promotion of hepatic
ﬁbrosis. Therefore, more systemic in-depth studies on gene
regulation and the microenvironment in BMSC differentiation
are needed to facilitate the effective control of BMSC prolif-
eration and accurately directed differentiation, allowing
BMSCs to be effectively applied in clinical treatment.
MT is a quinolizidine compound with the chemical formula
is C15H24N20. Its molecular backbone is a heterodimeric
quinolizidine ring. MT has anti-inﬂammatory, antiviral, anti-
ﬁbrotic, anti-arrhythmic, and immune-suppressive functions.
The drug is mainly used for the treatment of viral hepatitis,
hepatic ﬁbrosis, and arrhythmia, but it also has certain efﬁ-
cacy in the prevention and treatment of tumors (Zhang et al.,
2001; Zhang et al., 2011; Liu et al., 2014). MT can relieve
pathological injury to liver parenchymal cells and non-
parenchymal cells and has signiﬁcant inhibitory effects on
the proliferation of HSCs and ﬁbroblasts. The extensive
pharmacological activities of MT suggest that its mechanism
of action is complex. A thio derivative of MT, MASM, can act
directly on ribosomal protein S5 (RPS5) in vitro and in rats,
reducing the phosphorylation levels of Ser473 and Thr308 in
Akt and inhibiting HSC activation (Xu et al., 2014). However,
the pharmacological activity of MT is not high, making it
necessary to modify its structure to screen for derivatives
that have high activities and low toxicity. The aforementioned
MASM study conﬁrmed that the pharmacological activity of a
thio derivative of MT is greatly increased to that of MT and
the toxicities equivalent (Hu et al., 2010; Xu et al., 2014). We
performed modiﬁcations on the basis of thio derivatives of
MT. The methylamino group at position 18 was acetylated to
improve its stability, and an amino side chain was introduced
to increase it activity. This produced the novel MT derivatives
MD-1, MD-2, and MD-3, which had good stability and strong
activity.
MD-1, MD-2, and MD-3 had large differences in their
activities based on the different side chain groups. At
100 μmol/L, MD-1 reduced the survival rate of HSC-T6 cells
to around 20%, MD-2 reduced the cell survival rate to 27.4%,
and the inhibitory effect of MD-3 (47.2% cell survival rate)
was equivalent to that of MT (62.9% cell survival rate, Fig. 1).
These results suggest that MD-1 and MD-2 had inhibitory
effects on HSC-T6 cells, whereas MD-3 did not signiﬁcantly
improve upon the inhibitory effect of MT on HSC-T6 cells.
MD-1 signiﬁcantly inhibited the proliferation and migration of
HSC-T6 cells and induced G0/G1 arrest and apoptosis.
Although the mechanism underlying hepatic ﬁbrosis is
complex, the multi-functional transmembrane glycoprotein
EGFR speciﬁcally interacts with EGF and TGF-β1, causing
its dimerization and regulating cell growth, proliferation, and
differentiation (Voon et al., 2013). The EGFR-related signal
transduction pathways are activated in HSCs in liver injury
and chronic liver disease to promote the development and
progression of hepatic ﬁbrosis. Therefore, we focused on
studying the effect of MD-1 on the EGFR-related signal
transduction pathways. Immunoﬂuorescence showed that
the target molecule of MD-1 in HSC-T6 cells was EGFR.
MD-1 interacted with EGFR on the surface of cell mem-
branes, inhibiting EGFR phosphorylation. Inhibition of the
phosphorylation of downstream protein kinases, such as Akt,
affected the expression and activity of target proteins that
regulate cell proliferation, migration, cell cycle, and apopto-
sis, such as cyclin D1 and p-Smad, ﬁnally changing the
biological behaviors of cells. MD-1 reduced the synthesis
and secretion of ECM components, such as type I collagen
and type III collagen, in HSC-T6 cells, thereby exerting its
anti-hepatic ﬁbrosis activity. In the DMN-induced hepatic
ﬁbrosis model, MD-1 treatment delayed the development
and progression of hepatic ﬁbrosis, protected liver
parenchymal cells, and improved liver function. Although the
present study focused on the effect of MD-1 by inhibiting
EGFR activation, other signaling pathways, such as the Ras/
ERK pathway, may also be involved in hepatic ﬁbrosis.
Therefore, there are further studies needed to be carried out
on the mechanisms of MT derivatives.
In summary, the present study reports a novel synthe-
sized MT derivative, MD-1, that can signiﬁcantly inhibit HSC
activity, induce HSC apoptosis, and decrease the secretion
of ECM components by HSCs. The drug has a protective
effect on liver parenchymal cells in a rat DMN-induced
hepatic ﬁbrosis model. The possible mechanism by which
MD-1 exerts its biological functions may be via EGFR
binding on the cell surface, inhibiting its function and block-
ing the EGFR-related downstream signaling pathways.




The rat HSC-T6 cell line was a gift from the Molecular Cancer
Research Laboratory in the Eastern Hepatobiliary Surgery Hospital
of Second Military Medical University (Xu et al., 2015). Cells were
cultured in DMEM (GIBCO, New York, USA) containing 10% fetal
bovine serum (FBS) in a 5% CO2 atmosphere at 37°C. MT and its
derivatives were synthesized by the School of Pharmacy, Second
Military Medical University. The powder form of each compound
(2 mg) was added to 200 µL DMSO until completely dissolved, then
1800 µL ddH2O added to obtain a working solution of 1 mg/mL for
future use.
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HSC-T6 cells were cultured to the logarithmic phase and then
inoculated onto 96-well plates (104 cells/well) for 24 h. Different
gradient concentrations of MT and its derivatives MD-1, MD-2, and
MD-3 were added. Each concentration group had eight replicate
wells. After cells were cultured for another 24 h, cell proliferation was
detected using the Cell Counting Kit-8 (CCK-8) reagent kit (Dojindo
Molecular Technologies, Inc., Shanghai, China). Based on the IC50
values of the three drugs, MD-1, the one with the strongest activity,
was selected for other experiments.
Cell motility
Transwells were placed in 24-well plates and HSC-T6 cells placed in
the top chamber (2 × 105 cells/200 µL). The bottom chamber con-
tained 500 µL culture medium containing 10% FBS. Cells in the top
chambers were treated with MD1 or MT at the corresponding IC50
(62 µmol/L or 128 µmol/L, respectively). A control group without drug
was used for comparison. After 48 h of culture, cells in the top layer
of the Transwell were wiped and stained with 0.1% crystal violet for
15 min. Three ﬁelds were randomly selected under a light micro-
scope (200× magniﬁcations) for cell counting and photography.
Experiments were performed in three biologically independent
replicates.
Detection of cell cycle and cell apoptosis
HSC-T6 cells were inoculated onto a 6-well plate at 5 × 105 cells/
well. MD-1 or MT was added at 62 μmol/L. After 48 h, the cells were
collected and washed twice with pre-cooled PBS. Some cells were
ﬁxed in pre-cooled 75% ethanol in a 4°C refrigerator overnight,
washed with PBS twice, and stained with propidium iodide (PI)
containing RNase in the dark for 30 min. Cell cycle phase was
detected using a ﬂow cytometer (FACS420, BD Biosciences, San
Jose, CA). The other cells were used for annexin V/PI staining. The
apoptosis rate was also determined by ﬂow cytometry.
Binding and inhibiting EGFR
The shRNA plasmid pGenensil-shEGFR, targeting the rat EGFR
gene, and a negative control vector, pGenesil-shMC, were con-
structed by Wuhan Genesil Biotechnology Co., Ltd. (Wuhan,
China). The 21-nt sequence of EGFR-shRNA targeted base pairs
2268–2290 (5′-gga tat taa agg aaa cag aat-3′) of the EGFR gene
(GenBank: M37394.2). A mock control shRNA vector (shMC: 5′-
gac ttc ata agg cgc atg cat-3′) was concomitantly constructed.
HSC-T6 cells were inoculated on a 6-well plate at 5 × 105 cells/
well. The shRNA plasmids were transfected into HSC-T6 cells
using Lipofectamine 2000 (Invitrogen Corporation Shanghai Rep-
resentative Ofﬁce, Shanghai, China). After 48 h of continuous
culture, cells were screened using G418 (400 μg/mL). The
obtained cells were named HSC-T6-shEGFR and HSC-T6-shMC
cells.
HSC-T6, HSC-T6-shEGFR, and HSC-T6-shMC cells were inoc-
ulated onto 6-well plates at 5 × 105 cells/well. Biotin-labeled MD-1
(MD-1-Biotin) was added at a concentration of 62 μmol/L. After
culturing for another 48 h, the cells were collected. A part of cells
were lysed in RIPA protein lysis buffer and the harvested proteins
subjected to Western blot for detection of EGFR expression. A part
of cells were smeared onto slides for immunoﬂuorescence double
labeling to localize MD-1-Biotin and EGFR. The working concen-
tration of FITC-conjugated goat anti-rat EGFR and TRITC-conju-
gated anti-biotin antibodies was 1:1000 (Cell Signaling Technology,
Inc., Beverly, MA). The rest of cells were prepared for the co-im-
munoprecipitation assay using the corresponding speciﬁc antibodies
for MD-1-Biotin and EGFR.
Detection of EGFR signal transduction pathway-associated
proteins
HSC-T6 cells were inoculated onto 6-well plates at 5 × 105 cells/well.
MD-1 was added at a concentration of 62 μmol/L. After 48 h, the
cells were collected and lysed in RIPA protein lysis buffer (Life
Technologies Corporation, New York, USA). Total protein was
extracted for Western blot detection of downstream proteins in the
EGFR signal transduction pathway. The primary antibodies included
EGFR, p-EGFR, AKT, p-AKT (Cell Signaling Technology, Danvers,
MA), Survivin, cyclin D1 (Abcam Inc., Cambridge, MA), and p-Smad
(Santa Cruz Biotech Inc., CA).
Detection of ECM proteins
HSC-T6 cells were inoculated onto 6-well plates at 5 × 105 cells/well.
MD-1 was added at a concentration of 62 μmol/L. After 48 h, the
cells and culture supernatant were collected. Cells were treated with
TRIzol (Life Technologies Corporation, New York, USA) to extract
total RNA for real-time quantitative RT-PCR (qRT-PCR) of ECM
indicators using the PrimeScript RT Reagent Kit (TaKaRa Inc.,
Dalian, China). The primer sequences were: β-actin (537 bp),
upstream 5′-ACC CAC ACT GTG CCC ATC TAT G-3′ and down-
stream 5′-AGA GTA CTT GCG CTC AGG A-3′; α-SMA (120 bp),
upstream 5′-CCG AGA TCT CAC CGA CTA CC-3′ and downstream
5′-TCC AGA GCG ACA TAG CAC AG-3′; type III collagen (438 bp),
upstream 5′-AGG CCA ATG GCA ATG TAA AG-3′ and downstream
5′-TAT TGG GTG AA A CAG CA-3′; TIMP-1 (250 bp), 5′-TCC CCA
GAA ATC GAG AC-3′ and downstream 5′-TCA GAT TAT GCC AGG
GAA CC-3′. The cell culture supernatant was used to detect ECM
indicators by ELISA (Shanghai Westang Bio-Tech Co., Ltd, Shang-
hai, China).
Construction of the rat hepatic ﬁbrosis model
A total of 20 male SD rats (Shanghai SLAC Laboratory Animal Co.,
Ltd, Chinese Academy of Sciences, Shanghai, China) at 4 weeks of
age and a body weight of 80–100 g were randomly divided into four
groups of ﬁve animals each: normal control group, model control
group, MT group, and MD-1 group. Except for the normal control
group, the rats were intraperitoneally injected with 1% DMN solution
(10 μg/kg). Injections were performed three times each week
(Monday, Wednesday, and Friday) for four consecutive weeks. The
normal control group received an equal volume of normal saline.
Starting from week 5, rats in the MT and MD-1 groups were treated
with the drug of interest via intragastric administration (62 μmol/L/kg)
three times each week (Monday, Wednesday, and Friday) for four
consecutive weeks. The blank control group and model control
group received of an equal volume of normal saline via intragastric
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administration. After the drug treatment was ﬁnished, animals were
continuously fed for 2 months.
Rats were sacriﬁced after anesthesia. Blood and liver tissues
were collected for evaluation of liver function and liver ﬁbrosis indi-
cators. The liver was ﬁxed in 10% formalin for 6 h, embedded in
parafﬁn, and sectioned. Staining was performed using the Van
Gieson staining reagent kit (Maxim Biotechnology Development Co.
Ltd, Fuzhou, China) according to the manufacturer’s instructions.
Fibrosis was observed under a microscope. p-EGFR, p-AKT, α-
SMA, cyclin D1, and p-Smad were detected by immunohistochem-
istry. Serum ALT, AST, and type I collagen were detected by ELISA.
All animal experiments were approved by the Animal Ethics Com-
mittee of Second Military Medical University (Shanghai, China).
Statistical analysis
Experimental data are presented as mean ± SD. One-way ANOVA
was performed using SPSS (version 18.0). The least signiﬁcant
differences (LSD) test was performed if variances were homoge-
neous, and Dunnett’s T3 method was used if variances were
heterogeneous. A P value < 0.05 was considered signiﬁcant.
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